Avista Healthcare
NEW YORK and CORAL GABLES, Fla., May 2, 2018 /PRNewswire/ — Avista Capital Partners (“Avista”), a leading private equity firm, in partnership with Dana Holdings, a consumer healthcare-focused private investment group, today announced the completion of its acquisition of Kramer Laboratories, Inc. (“Kramer Laboratories,” “Kramer” or “the Company”), a marketer of over-the-counter (OTC) foot care and specialty cough products. Kramer, […]
WILMINGTON, Mass.–(BUSINESS WIRE)–Apr. 3, 2018– Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of MPI Research for approximately $800 million in cash, subject to certain customary adjustments. MPI is a premier non-clinical contract research organization (CRO) providing comprehensive testing services to biopharmaceutical and medical device companies worldwide. Acquiring MPI will enhance Charles […]
YARDLEY, Pa., March 15, 2018 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinosewas named the Emerging Company of the Year by Life Sciences Pennsylvania at its Annual Dinner last night. Additionally, at the ceremony and as previously announced, CEO Peter Miller was presented with the 2017 Frank […]
YARDLEY, Pa., Feb. 20, 2018 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller has been chosen as the 2017 Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania. Additionally, Optinose has been honored as a finalist […]
Bridgewater, NJ – February 19, 2018 – Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous system (CNS) treatments utilizing its proprietary osmotic drug delivery platform, announced today that the U.S. Food and Drug Administration (FDA) has approved OSMOLEX ER™, an amantadine extended release tablet, for the […]
NEW YORK, NY / LONDON, UK – February 8, 2018 – Funds advised by BC Partners (“BC Partners”), a leading international investment firm, today announced the signing of a definitive agreement whereby BC Partners will acquire Zest Dental Solutions (“Zest”) from Avista Capital Partners (“Avista”), a leading private equity firm in the healthcare sector. Financial […]
Princeton, N.J.— January 10, 2018 — Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that the Company has completed a $110 million mezzanine round of financing led by Wellington Capital Management. Other new investors participating in the financing include Avista Capital Partners, RA Capital Management, New Leaf Venture Partners, Deerfield Management, and Rock Springs Capital. Apple Tree Partners, the […]
IRVING, Texas, January 8, 2018 — Miraca Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic […]
St. Louis and New York, November 27, 2017 – Express Scripts (NASDAQ: ESRX) and Avista Capital Partners, a leading private equity firm, announced today that Avista has signed a definitive agreement to acquire United BioSource (UBC), a wholly-owned subsidiary of Express Scripts Holding Company. Founded in 2003 and headquartered in Blue Bell, Pennsylvania, UBC is […]
IRVING, Texas and NEW YORK, Nov. 20, 2017 – /PRNewswire/ — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc. MLS is one of the largest independent anatomic pathology labs in the United States. The Company […]
Yardley, PA, Oct. 17, 2017 – OptiNose, Inc. (NASDAQ:OPTN), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $16.00 […]
IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Since its acquisition by MHD […]